CNS Pharmaceuticals Form 4 shows 1,517 director options to 2035

Rhea-AI Filing Summary

CNS Pharmaceuticals, Inc. (CNSP) reported a stock option grant to one of its directors on Form 4. On November 17, 2025, the director received an option to purchase 1,517 shares of common stock at an exercise price of $12.48 per share, with an expiration date of November 17, 2035.

The option was originally approved by the compensation committee on June 6, 2025, and became effective after shareholders approved the underlying stock option plan on November 17, 2025, described as the Shareholder Approval Date. The options vest in four equal quarterly installments starting on that approval date, conditioned on the director’s continued employment with the company. The filing notes that the option was issued in connection with the reporting person’s employment and is held as a direct ownership position.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gumulka Jerzy

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to purchase common stock	1,517	$0.00	--

Holdings After Transaction: Option to purchase common stock — 1,517 shares (Direct)

Footnotes (1)

1. The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date"). The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date. Issued in connection with the reporting person's employment with the Company.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gumulka Jerzy

(Last) (First) (Middle)

C/O CNS PHARMACEUTICALS, INC.

100 WEST LOOP SOUTH, SUITE 900

(Street)

HOUSTON TX 77027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CNS Pharmaceuticals, Inc. [ CNSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$12.48	11/17/2025(1)		A		1,517		(2)	11/17/2035	Common Stock	1,517	$0(3)	1,517	D

Explanation of Responses:

1. The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date").

2. The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date.

3. Issued in connection with the reporting person's employment with the Company.

	/s/ Christopher Downs, Attorney-in-Fact	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CNSP disclose in this Form 4 filing?

CNS Pharmaceuticals, Inc. disclosed that a director received an option to purchase 1,517 shares of common stock on November 17, 2025 under the company’s stock option plan.

What is the exercise price and term of the CNSP stock options reported?

The director’s option allows the purchase of CNS Pharmaceuticals common stock at an exercise price of $12.48 per share and carries an expiration date of November 17, 2035.

How do the CNSP director’s stock options vest?

The options vest in four equal quarterly installments beginning on the Shareholder Approval Date of November 17, 2025, subject to the reporting person’s continued employment on each vesting date.

When was the CNSP stock option plan and grant approved?

The option grant was approved by the compensation committee on June 6, 2025, and the stock option plan was approved by shareholders at the annual meeting on November 17, 2025.

What is the nature of the reporting person’s relationship to CNSP?

The reporting person is identified as a Director of CNS Pharmaceuticals, Inc., and the option was issued in connection with the reporting person’s employment with the company.

Is the CNSP director’s stock option held directly or indirectly?

The Form 4 indicates the reporting person’s 1,517 stock options are held directly.